ICRAKI: Initial Intermittent Dialysis Linked to Higher Mortality Than Continuous Therapy
This contemporary randomized trial challenges long-held equipoise between intermittent hemodialysis and continuous renal-replacement therapy as the initial modality in critically ill patients with acute kidney injury, with direct relevance to ICU pharmacists managing hemodynamics, drug dosing, and dialysis-related electrolyte and drug clearance.
📅 Journal publication: Oct 29, 2026(online Oct 14, 2026)·Last updated: Nov 7, 2026
Renal-replacement therapy choice impacts outcomes in acute kidney injury management for critically ill patients. Intermittent hemodialysis showed higher mortality (63.1%) compared to continuous therapy (53.5%) for major adverse kidney events by day 90. Continuous renal-replacement therapy may reduce mortality compared to intermittent hemodialysis in critically ill acute kidney injury patients. Continuous renal-replacement therapy may be preferred over intermittent hemodialysis in acute kidney injury for better survival outcomes.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Free account, no credit card. Includes 1 full deep analysis every month.
Authors:Gaudry S, Boubaya M, Louis G, Chaïbi K, de Montmollin E, Bohé J, Desgrouas M, Devautour C, Joseph A, Mégarbane B, Camus C, Bailly P, Lambour A, Arrestier R, Jaber S, Robine A, Chudeau N, Chevrel G, La Combe B, Nicolas J, Argaud L, Bureau C, Kimmoun A, Zucman N, Ricard JD, Thiery G, Faguer S, Jozwiak M, Ferrand N, Chousterman B, Marzouk M, Cadiet J, Combes A, Mari A, Contou D, Amathieu R, Da Silva D, Gandonnière CS, Rodie-Talbere PA, Durand-Zaleski I, Rossignol P, Quenot JP, Biard L, Bloch C, Dreyfuss D, ICRAKI Trial Group
Citation:Gaudry S, Boubaya M, Louis G, et al. Intermittent or Continuous Renal-Replacement Therapy in Acute Kidney Injury. The New England journal of medicine. 2026;395(17):1677-1690. doi:10.1056/NEJMoa2608397